Company · Public · VRMB
Veri Metabolic
Combines continuous metabolic measurement with a therapeutics pipeline targeting insulin resistance in aging.
EvidenceModeratePlatform revenue expanding
Listing
Public
Ticker
VRMB
Headquarters
Copenhagen, DK
Founded
2015
Technology
Metabolic health measurement and therapeutics
Category
Market cap
$3.8B
Longevity thesis
Metabolic dysfunction is the earliest measurable driver of age-related disease, making it the most commercially tractable entry point.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| VM-220 | Phase 2 | Insulin sensitivity in older adults |
| Continuous metabolic platform | Commercial | Measurement |
Recent developments
- 6 Aug 2026Expanded measurement platform into clinical trial services.
Scientific evidence
EvidenceModerate
Measurement business is validated; therapeutic claims are not yet.
LONGEFI analysis
The measurement layer is where longevity revenue currently exists. LONGEFI separates that from therapeutic upside.
Analysis is research commentary. It is not investment advice or a recommendation.